Japan makes exception; signs historic nuclear deal with India

November 11, 2016

Tokyo, Nov 11: Making an exception, Japan today signed a historic civil nuclear cooperation deal with India, opening the door for collaboration between their industries in the field even as the countries signed nine other agreements in various areas to bolster bilateral ties.Japan-India

The agreements, including the one for cooperation in peaceful uses of nuclear energy, marks a historic step in their engagement to build a clean energy partnership, Prime Minister Narendra Modi said after wide-ranging talks with his Japanese counterpart Shinzo Abe.

The nuclear agreement comes after tough negotiations for over six years between the two countries and Abe said at the joint media interaction with Modi that he was delighted over the signing of agreement on peaceful use of nuclear energy.

"This agreement is a legal framework that India will act responsibly in peaceful uses of nuclear energy and also in Non-Proliferation regime even though India is not a participant or signatory of NPT," he said.

"It (the agreement) is in line with Japan's ambition to create a world without nuclear weapons," said Abe, whose country has traditionally adopted a tough stand on proliferation issues having been the only victim of atomic bombings during World War II.

He noted that India in September 2008 had made its intention of peaceful uses of nuclear energy and also announced moratorium on nuclear tests.

"Today's signing of the Agreement for Cooperation in Peaceful Uses of Nuclear Energy marks a historic step in our engagement to build a clean energy partnership," Modi said.

"Our cooperation in this field will help us combat the challenge of Climate Change. I also acknowledge the special significance that such an agreement has for Japan," he said and thanked Abe, Japanese government and Parliament for their support to this agreement.

Other nations who have signed civil nuclear deal with India include the US, Russia, South Korea, Mongolia, France, Namibia, Argentina, Canada, Kazakhstan and Australia.

In his remarks, Prime Minister Modi said as democracies, the two countries "support openness, transparency and the rule of law".

"We are also united in our resolve to combat the menace of terrorism, especially cross-border terrorism," he said.
Later, speaking at a Banquet hosted by Abe in his honour, Modi said there is also a lot that the two sides can do together as close partners, not just for the benefit of their societies, but also for the region and the whole world.

"Our capacities could also combine to respond to both, the opportunities and challenges that we jointly face in present times. And, together with the global community we can, and we must, combat the rising threats of radicalisation, extremism and terrorism," he said.

Abe pushed for universalization of the NPT, entry into force of Comprehensive Nuclear-Test-Ban Treaty (CTBT) and start of negotiations at the earliest on Fissile Material Cutoff Treaty (FMCT).

"The two Prime Ministers welcomed the signing of the Agreement between the Government of Japan and the Government of the Republic of India for Cooperation in the Peaceful Uses of Nuclear Energy which reflects a new level of mutual confidence and strategic partnership in the cause of clean energy, economic development and a peaceful and secure world," said a joint statement.

Modi said deeper economic engagement, growth of trade, manufacturing and investment ties, focus on clean energy, partnership to secure the citizens, and cooperation on infrastructure and skill development are among key priorities.

"India and its economy are pursuing many transformations. Our aim is to become a major centre for manufacturing, investments and for the 21st century knowledge industries.

"And, in this journey, we see Japan as a natural partner. We believe there is vast scope to combine our relative advantages, whether of capital, technology or human resources, to work for mutual benefit," he said in his joint interaction.

The Prime Minister said that the strategic partnership between the two countries also brings peace, stability and balance to the region. It is alive and responsive to emerging opportunities and challenges in Asia-Pacific, he said.

The successful Malabar naval exercise has underscored the convergence in the two sides' strategic interests in the broad expanse of the waters of the Indo-Pacific, Modi said.

On his part, Abe mentioned the high speed train corridor between Mumbai and Ahmedabad that is being built with the help of Japan, saying the project symbolizes a new dimension in the special relations.

Prime Minister Abe said the designing of the project will begin by the end of this year, construction will begin in 2018 and the high speed train will be in service from 2023.

He said Modi, who will travel by one such train to Kobe city tomorrow from here, will see for himself that it is the safest technology in the world.

The Japanese private sector also would be setting up an institute of manufacturing in India to train about 30,000 people in 10 years, particularly in rural areas, Abe said.

Abe said Japan will set up a tourism bureau in New Delhi to encourage people-to-people contacts. He said he wants to work with Modi in liberalizing the visa rules.

"India-Japan relations have the greatest potential in the world. Strong India is in the best interest of Japan and strong Japan is in the best interest of India," Abe said.

Noting that he had met Modi for the third time in one year, Abe praised him, saying he had a "global vision" and was a "decisive leader".

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 15,2020

Dubai, Jun 15: The global tally of Covid-19 coronavirus infections crossed the 8 million mark on Monday, with recoveries at 4.13 million, and deaths at nearly 436,000.

As of 11.40am UAE time, there were 3.43 active Covid-19 cases globally, of which 54,460 were serious or critical.

The United States still leads the charts with 2.16 million cases and 117,858 deaths. Behind US, at a distant No 2, is Brazil with 867,882 cases and 43,389 deaths.

Russia, India, the UK, Spain, Italy, Peru, Germany and Iran complete the top 10.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
May 6,2020

Italian researchers have claimed that they have successfully developed a vaccine to contain coronavirus (COVID-19) which is likely to work on humans, a report said.

Luigi Aurisicchio, CEO of Takis, the firm developing the medication, said that a coronavirus candidate vaccine has neutralised the virus in human cells for the first time, the Arab News reported.

"This is the most advanced stage of testing of a candidate vaccine created in Italy. Human tests are expected after this summer," Aurisicchio was quoted as saying to Italian news agency ANSA.

"According to the Spallanzani Hospital, as far as we know we are the first in the world so far to have demonstrated neutralisation of the coronavirus by a vaccine. We expect this to happen in humans too," he added.

The researchers experimented with the vaccine on mice that had successfully developed antibodies that blocked the virus from infecting the cells. They further observed that the five vaccine candidates generated a large number of antibodies, and selected two with the best results.

All of the vaccine candidates currently being developed are based on the genetic material of DNA protein "spike", the molecular tip used by the coronavirus to enter human cells.

They are injected with the so-called "electroporation" technique, which consists of an intramuscular injection followed by a brief electrical impulse, helping the vaccine break into the cells and activating the immune system, the report said.

Researchers believe that this makes their vaccine particularly effective for generating functional antibodies against the "spike" protein, in particular in the lung cells, which are the most vulnerable to coronavirus.

"We are working hard for a vaccine coming from Italian research, with an all-Italian and innovative technology, tested in Italy and made available to everyone," Aurisicchio was quoted by the Arab News report.

"In order to reach this goal, we need the support of national and international institutions and partners who may help us speed up the process," he noted.

The total number of COVID-19 infections, fatalities and recoveries since the pandemic began has risen to 213,013 in the country.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 7,2020

Russia boasts that it's about to become the first country to approve a Covid-19 vaccine, with mass vaccinations planned as early as October using shots that are yet to complete clinical trials -- and scientists worldwide are sounding the alarm that the headlong rush could backfire.

Moscow sees a Sputnik-like propaganda victory, recalling the Soviet Union's launch of the world's first satellite in 1957.

But the experimental Covid-19 shots began first-in-human testing on a few dozen people less than two months ago, and there's no published scientific evidence yet backing Russia's late entry to the global vaccine race, much less explaining why it should be considered a front-runner.

“I'm worried that Russia is cutting corners so that the vaccine that will come out may be not just ineffective, but also unsafe,” said Lawrence Gostin, a global public health law expert at Georgetown University. “It doesn't work that way... Trials come first. That's really important.”

According to Kirill Dmitriev, head of Russia's Direct Investment Fund that bankrolled the effort, a vaccine developed by the Gamaleya research institute in Moscow may be approved in days, before scientists complete what's called a Phase 3 study.

That final-stage study, usually involving tens of thousands of people, is the only way to prove if an experimental vaccine is safe and really works.

Health Minister Mikhail Murashko said members of “risk groups,” such as medical workers, may be offered the vaccine this month.

He didn't clarify whether they would be part of the Phase 3 study that is said to be completed after the vaccine receives “conditional approval.”

Deputy Prime Minister Tatyana Golikova promised to start “industrial production” in September, and Murashko said mass vaccination may begin as early as October.

Dr Anthony Fauci, the top US infectious disease specialist, questioned the fast-track approach last week.

“I do hope that the Chinese and the Russians are actually testing a vaccine before they are administering the vaccine to anyone, because claims of having a vaccine ready to distribute before you do testing I think is problematic at best," he said.

Questions about this vaccine candidate come after the US, Britain and Canada last month accused Russia of using hackers to steal vaccine research from Western labs.

Delivering a vaccine first is a matter of national prestige for the Kremlin as it tries to assert the image of Russia as a global power capable of competing with the US and China.

The notion of being “the first in the world” dominated state news coverage of the effort, with government officials praising reports of the first-step testing.

In April, President Vladimir Putin ordered state officials to shorten the time of clinical trials for a variety of drugs, including potential coronavirus vaccines.

According to Russia's Association of Clinical Trials Organizations, the order set “an unattainable bar” for scientists who, as a result, "joined in on the mad race, hoping to please those at power.”

The association first raised concern in late May, when professor Alexander Gintsburg, head of the Gamaleya institute, said he and other researchers tried the vaccine on themselves.

The move was a “crude violation of the very foundations of clinical research, Russian law and universally accepted international regulations" the group said in an open letter to the government, urging scientists and health officials to adhere to clinical research standards.

But a month later, the Health Ministry authorized clinical trials of the Gamaleya product, with what appeared to be another ethical issue.

Human studies started June 17 among 76 volunteers. Half were injected with a vaccine in liquid form and the other half with a vaccine that came as soluble powder.

Some in the first half were recruited from the military, which raised concerns that servicemen may have been pressured to participate.

Some experts said their desire to perform well would affect the findings. “It's no coincidence media reports we see about the trials among the military said no one had any side effects, while the (other group) reported some," said Vasily Vlassov, a public health expert with Moscow's Higher School of Economics.

As the trials were declared completed and looming regulatory approval was announced last week, questions arose about the vaccine's safety and effectiveness.

Government assurances the drug produced the desired immune response and caused no significant side effects were hardly convincing without published scientific data describing the findings.

The World Health Organization said all vaccine candidates should go through full stages of testing before being rolled out.

“There are established practices and there are guidelines out,” WHO spokesman Christian Lindmeier said Tuesday.

“Between finding or having a clue of maybe having a vaccine that works, and having gone through all the stages, is a big difference.”

Offering an unsafe compound to medical workers on the front lines of the outbreak could make things worse, Georgetown's Gostin said, adding: “What if the vaccine started killing them or making them very ill?”

Vaccines that are not properly tested can cause harm in many ways — from a negative impact on health to creating a false sense of security or undermining trust in vaccinations, said Thomas Bollyky, director of the global health program at the Council on Foreign Relations. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.